230 related articles for article (PubMed ID: 35989070)
1. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
Lee JW; Ahn HS; Chang J; Kang HY; Chang DJ; Suh JK; Lee H
Korean J Ophthalmol; 2022 Oct; 36(5):423-434. PubMed ID: 35989070
[TBL] [Abstract][Full Text] [Related]
2. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
[TBL] [Abstract][Full Text] [Related]
3. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
[TBL] [Abstract][Full Text] [Related]
4. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
Walters TR; Ahmed IIK; Lewis RA; Usner DW; Lopez J; Kopczynski CC; Heah T;
Ophthalmol Glaucoma; 2019; 2(5):280-289. PubMed ID: 32672669
[TBL] [Abstract][Full Text] [Related]
5. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Leary KA; Steibel JP; Harman CD; Anderson AL; Komáromy AM
Vet Ophthalmol; 2021 Nov; 24(6):610-619. PubMed ID: 34085750
[TBL] [Abstract][Full Text] [Related]
7. One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Phase 3, Randomized MERCURY-1 Study.
Brubaker JW; Teymoorian S; Lewis RA; Usner D; McKee HJ; Ramirez N; Kopczynski CC; Heah T
Ophthalmol Glaucoma; 2020; 3(5):327-338. PubMed ID: 32768361
[TBL] [Abstract][Full Text] [Related]
8. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
[TBL] [Abstract][Full Text] [Related]
9. Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.
Radell JE; Serle JB
Drugs Today (Barc); 2019 Sep; 55(9):563-574. PubMed ID: 31584573
[TBL] [Abstract][Full Text] [Related]
10. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
Singh IP; Fechtner RD; Myers JS; Kim T; Usner DW; McKee H; Sheng H; Lewis RA; Heah T; Kopczynski CC
J Glaucoma; 2020 Oct; 29(10):878-884. PubMed ID: 32826769
[TBL] [Abstract][Full Text] [Related]
11. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Mehran NA; Sinha S; Razeghinejad R
Eye (Lond); 2020 Jan; 34(1):72-88. PubMed ID: 31695162
[TBL] [Abstract][Full Text] [Related]
12. Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
Wisely CE; Sheng H; Heah T; Kim T
Adv Ther; 2020 Mar; 37(3):1114-1123. PubMed ID: 31981106
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials.
Luo N; Jiang X; Hao M; Fang Z; Wei Y; Zhang W
Front Med (Lausanne); 2022; 9():923308. PubMed ID: 35979215
[TBL] [Abstract][Full Text] [Related]
14. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013
[TBL] [Abstract][Full Text] [Related]
15. Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension.
Shahid S; Rizvi SWA; Khan AA; Ashraf H; Akhter A
Indian J Ophthalmol; 2024 Mar; 72(3):427-431. PubMed ID: 38146971
[TBL] [Abstract][Full Text] [Related]
16. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
Diestelhorst M; Larsson LI;
Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
[TBL] [Abstract][Full Text] [Related]
18. [ROCK (RHO-KINASE INHIBITORS) FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION].
Hayat H; Achiron A; Masarwa D; Goldberg M
Harefuah; 2023 Mar; 162(3):160-164. PubMed ID: 36966373
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
[TBL] [Abstract][Full Text] [Related]
20. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
